---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-020539"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T07:06:10.060560+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics Q1 net loss $16.8M; Celltrion partnership and FDA feedback on RT-102

## Summary
- Net loss of $16.8M for Q1 2023, up from $13.8M in Q1 2022; non-cash stock compensation $4.0M.
- Cash and equivalents $86.8M as of Mar 31, 2023; expected to fund operations to mid-2024.
- Announced partnership with Celltrion to develop RT-111, an oral ustekinumab biosimilar.
- FDA preliminary feedback supports 505(b)(2) pathway for RT-102 (osteoporosis); Phase 2 expected 2H 2023.
- Three Phase 1 studies expected in 2023: RT-111, RT-105 (adalimumab biosimilar), RT-110 (parathyroid hormone).

## SEC filing metadata
- accession: 0000950170-23-020539
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000095017023020539/0000950170-23-020539-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000095017023020539/rani-20230510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-020539
- JSON: https://secwatch.observer/filing/0000950170-23-020539.json
- Plain text: https://secwatch.observer/filing/0000950170-23-020539.txt

## Key facts
- Earnings Releases
  Rani Therapeutics Holdings, Inc. reported the three months ended March 31, 2023 results: net income $16.8 million.
  - Period: the three months ended March 31, 2023
  - Net income: $16.8 million
  - Result: reported results
  source text: Net loss for the three months ended March 31, 2023 was $16.8 million, compared to $13.8 million for the same period in 2022, including non-cash charges primarily attributable to stock-based compensation expense of $4.0 million for the three months ended March 31, 2023, compared to $3.0 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1856725/000095017023020539/0000950170-23-020539-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.